Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Alaska Air Group Reports December 2015 and Full-Year Operational Results
Source: PR Newswire (US)
SEATTLE, Jan. 5, 2016 /PRNewswire/ -- Alaska Air Group Inc. (NYSE: ALK) today reported December 2015 and year-end operational results on a consolidated basis, and for its subsidiaries, Alaska Airlines and Horizon Air. Detailed information is provided below.
AIR GROUP (including flights operated by third parties)
On a combined basis, Air Group reported a 9.9 percent increase in traffic on a 12.2 percent increase in capacity compared to December 2014. Load factor decreased 1.7 points to 83.3 percent. These statistics include flights operated by Alaska and those under capacity purchase arrangements, including Horizon, SkyWest and a small third-party carrier in the state of Alaska.
The following table shows the operational results for December and full-year 2015, compared to the prior-year periods:
December
Full-Year
2015
2014
Change
2015
2014
Change
Revenue passengers (in thousands)
2,732
2,559
6.8%
31,883
29,278
8.9%
Revenue passenger miles RPM (in millions)
2,976
2,707
9.9%
33,578
30,718
9.3%
Available seat miles ASM (in millions)
3,574
3,184
12.2%
39,914
36,078
10.6%
Passenger load factor
83.3%
85.0%
(1.7) pts
84.1%
85.1%
(1.0) pts
ALASKA AIRLINES - MAINLINE
Alaska reported a 9.8 percent increase in traffic on a 12.1 percent increase in capacity compared to December 2014. Load factor decreased 1.8 points to 83.6 percent. Alaska also reported 85.3 percent of its flights arrived on time in December, compared to the 80.0 percent reported in December 2014.
The following table shows Alaska's operational results for December and full-year 2015, compared to the prior-year periods:
December
Full-Year
2015
2014
Change
2015
2014
Change
Revenue passengers (in thousands)
1,965
1,830
7.4%
22,869
20,972
9.0%
RPMs (in millions)
2,694
2,453
9.8%
30,340
27,778
9.2%
ASMs (in millions)
3,221
2,874
12.1%
35,912
32,430
10.7%
Passenger load factor
83.6%
85.4%
(1.8) pts
84.5%
85.7%
(1.2) pts
On-time arrivals as reported to U.S. DOT
85.3%
80.0%
5.3 pts
86.4%
86.0%
0.4 pts
HORIZON AIR
Horizon reported a 0.5 percent decrease in traffic on a 0.9 percent increase in capacity compared to December 2014. Load factor decreased 1.1 points to 79.7 percent. Horizon also reported 66.6 percent of its flights arrived on time in December, compared to the 81.0 percent reported in December 2014.
The following table shows Horizon's operational results for December and full-year 2015, compared to the prior-year periods:
December
Full-Year
2015
2014
Change
2015
2014
Change
Revenue passengers (in thousands)
658
652
0.9%
7,910
7,455
6.1%
RPMs (in millions)
188
189
(0.5)%
2,305
2,207
4.4%
ASMs (in millions)
236
234
0.9%
2,886
2,780
3.8%
Passenger load factor
79.7%
80.8%
(1.1) pts
79.9%
79.4%
0.5 pts
On-time arrivals
66.6%
81.0%
(14.4) pts
82.8%
88.0%
(5.2) pts
Alaska Airlines, a subsidiary of Alaska Air Group (NYSE: ALK), together with its partner regional airlines, serves more than 100 cities through an expansive network in the United States, Canada, Mexico and Costa Rica. Alaska Airlines ranked "Highest in Customer Satisfaction Among Traditional Carriers in North America" in the J.D. Power North America Airline Satisfaction Study for eight consecutive years from 2008 to 2015. Alaska Airlines' Mileage Plan also ranked "Highest in Customer Satisfaction with Airline Loyalty Rewards Programs" in the J.D. Power 2014 and 2015 Airline Loyalty/Rewards Program Satisfaction Report. For reservations, visit www.alaskaair.com. For more news and information, visit Alaska Airlines' newsroom at www.alaskaair.com/newsroom.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/alaska-air-group-reports-december-2015-and-full-year-operational-results-300199078.html
SOURCE Alaska Air Group
Copyright 2016 PR Newswire
DAL reports traffic tomorrow am I correct?
Yeah agreed. I think GSCO is sticking it to us because we are exposed so heavily to China. It'll bottom and recover. $38 is typically the floor, so we can either hover here, drop there, or bounce from here.
Yeah this is the same thing. I think S&P got a correction. Good news is that I'm hoping this is the bottom and we recover the rest of the week. The. Again, China could get ripped apart again tonight.
-36% wow.
I was informed of the China -7% growth this morning and subsequent trading halt there. That's pretty bad...
Hey last January-February we went from $44 to $56. Would love to see that kind of action a second go around...
Well Fellas, the bad news is that we are ending 2015 down 5% on the year after all those big expectations in 2014.
The good news is that I just saved a bunch of money on my car insurance by switching over to Geico.
The Even better news is that we saw a surge in airline stocks to new highs last January before they plunged to lows. So, I'm looking for the top end of this trading range near the end of January.
What a crappy year it was for this stock, and I don't know what next year brings in the market, but it could have been much worse. Who knows, could be a Cinderella year next year. Then again it could also be a Cinderella AFTER MIDNIGHT year too.
But hey here's to a better 2016. I know I've seemed pessimistic, often, but honestly I try to play devils advocate and be realistic knowing how these guys are moving stocks nowadays.
Happy New Year fellas...
P.S this will be what our third year together!?? Time flies...
4:12pm - 7:59pm straight up dump fest. All unloading.
Fed won't let that happen. I see Dow 20,000 as I believe Feds will halt future rate hikes if not drop the .25 basis points they just added. Oil will go back up in 2016. Should help the overall market.
At this point, I'm just hoping this continues to fall sharply on down to $38 (bottom of this trade range) so I can back up the truck and sell it all around $43-$44. Really the only way to play this in addition to options waaaay out.
CNBC goes from bullish last week, to bearish this week following Boeing downgrade.
Just reposting for folks who don't want to open the article from the link.
Unions Gearing up for Fight Over American Airlines Stock
Source: Dow Jones News
By Peg Brickley
Trouble is brewing again in the bankruptcy case of an American Airlines Group Inc. predecessor. Unions representing the company's workers say they are in danger of being shortchanged, while shareholders of the old AMR Corp. get another generous payoff.
Hundreds of millions of dollars of valuable stock is still stored up in bankruptcy reserve accounts, waiting for a final reckoning of the accounts from the 2011 bankruptcy of AMR, parent of American Airlines.
AMR is paying off its bankruptcy debts with shares of new American Airline stock. The shares have soared in value since December 2013, when AMR emerged from bankruptcy protection and merged with US Airways Group Inc.
AMR's bankruptcy was a rare case that produced value to spare for shareholders. According to court papers, investors in the old equity received more than $9.5 billion of new American shares in the four months following AMR's bankruptcy exit.
Unions representing pilots, flight attendants and other workers of AMR Corp. say they are being asked to take a haircut when the remaining stock is handed out while investors in the old equity get more than their fair share.
American spokesman Casey Norton said the company will respond with a court filing and is reviewing a bankruptcy-court motion the unions filed Tuesday, criticizing the company's distribution plan. "We are confident that, under the court's supervision, we have properly managed the distribution under the plan of reorganization," Mr. Norton said.
The Allied Pilots Association, the Association of Professional Flight Attendants and the Transport Workers Union of America AFL-CIO are getting ready to wrestle American over the stock on behalf of employees. The unions say they are being asked to take less now than they received in earlier rounds of distributions, while "professional investors" that gambled on AMR's stock and won get even richer.
Investors in the old equity have reaped "substantial proper gains" and don't need "unwarranted additional gains taken from the pockets of America's workers," union lawyers wrote in a court filing.
Stock of the old company purchased for 20 cents a share at AMR's low point translated into $41.81 in value as of Jan. 26, 2015, the labor lawyers reckon. The price has since dropped back.
The price appreciation that made old AMR one of the best investments of recent years is contributing to the dispute. There will be taxes to pay, and the unions say shareholders should be stuck with the bill, rather than AMR's employees and other unsecured creditors.
In March, American estimated it had a cushion of nearly $390 million in a reserve account that the company felt it wouldn't need. That is in addition to nearly $140 million American wanted to keep on hand in case it lost disputes over bankruptcy claims, and a separate reserve for special airplane claims.
That estimate was filed in connection with a failed bid for court permission to start handing out what is still stored in chapter 11 coffers. American hasn't yet filed papers renewing that motion, but union lawyers think such a move is imminent.
American has been swatting down bankruptcy claims. On Dec. 7, American won a $632 million bankruptcy claims fight that had made it all the way to a federal appeals court. Once those claims are classified as disallowed, American will have excess funds in the reserve, lawyers for the unions say.
A January hearing has been set in the U.S. Bankruptcy Court for the Southern District of New York on the union motion, which seeks a court order to force the company to honor its obligations under the chapter 11 plan.
Write to Peg Brickley at peg.brickley@wsj.com
(END) Dow Jones Newswires
December 18, 2015 12:15 ET (17:15 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
Rich Greenfield said its all about cable service... BS. He waited til the Star Wars release to pull this move.
Sub $22*
I'm eyeing those $21's, or at least sun $22.
White collar crime at its finest. Downgrade DIS at the release of Star Wars!!?? You kidding me? They'll break all kinds of records and sell all kinds of nerd merchandise. Can't believe these crooks actually showed face on TV justifying the downgrade...
Discourse: I hold no position here anymore, but had to comment on that downgrade.
Hit $40.70 quick on that open. Ended 2014 at $44. Looking like it'll end 2015 below that. Remember all the articles at the end of the year calling for huge upside to $70+ this year? Once bitten... Won't fool me in 2016.
It's not up. These are T trades.
Just stepped out of a 2 hour meeting hadn't even seen the market
Eagle Pharmaceuticals Reports Successful Outcomes from Safety and Efficacy Study of RYANODEX for Exertional Heat Stroke
Source: Business Wire
Use of RYANODEX with Current Standard of Care (SOC) Showed Substantial Evidence of Increased Effectiveness in Treating EHS than SOC Alone
Favorable Safety Data Shows No Significant Drug-Related Adverse Events in Patients Treated with RYANODEX
Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (Nasdaq:EGRX) today announced positive results from a recently-completed study evaluating the safety and efficacy of RYANODEX® (dantrolene sodium for injectable suspension) for the treatment of exertional heat stroke (“EHS”), an investigational new indication for the product.
“We are very encouraged by the results of this study and are optimistic about the data’s clinically meaningful implications for RYANODEX as a potential treatment for EHS. We believe that the study data successfully supports establishing the safety and efficacy of RYANODEX for the treatment of EHS, potentially expanding the product’s label to include EHS as an authorized second indication,” said Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals. “We are eager to work with the FDA to make this treatment available to medical practitioners who provide immediate care for EHS patients. We look forward to discussing the data and next steps with the FDA in the near future,” he added.
“RYANODEX, paired with the current standard of care treatment for EHS, substantially increased the percent of patients showing clinically meaningful improvement in their level of consciousness and experiencing improvement in neurological functioning as early as 15 minutes post randomization. RYANODEX, which can be reconstituted and administered in less than one minute, could potentially offer a significant new therapeutic option for EHS, a life threatening condition,” added Dr. Adrian Hepner, Executive Vice President Clinical Research, Regulatory and Medical Affairs.
EHS is the most severe form of heat-related illness, characterized by core body temperature of 104° F (40° C) or greater and significant neurological dysfunction, and carries high rates of morbidity and mortality. The central nervous system is very sensitive to hyperthermia, causing neurologic complications due to involvement of the cerebellum, basal ganglia, anterior horn cells, and cranial and peripheral nerves.
Multiple scientific publications, including Szold et al.1 and Sithinamsuwan et al.2, have reported that despite early diagnosis and aggressive body cooling, EHS remains associated with severe neurological damage.
EHS is one of the leading causes of death in young athletes and non-combat related deaths in the military. There are no drug products on the market today to treat this potentially fatal condition.
Study Design and Outcomes
The first of its kind, Eagle’s study was conducted from September 22-27, 2015, at the Emergency Departments of four hospitals during the Hajj pilgrimage in the Makkah region, Saudi Arabia. Due to the life-threatening, unpredictable and sudden nature of EHS, the study was required to be conducted in an emergency and acute-care medical setting.
The study was primarily designed to assess the change in the level of neurological impairment in subjects suffering from the symptoms of EHS, from baseline to 90 minutes post-randomization, using the Glasgow Coma Scale (“GCS”), a validated and widely used tool among clinicians. In Group A, a greater proportion of patients were restored to a level of minor or no brain injury as compared to Group B.
The use of a validated and well-known instrument to evaluate neurological functioning, such as the Glasgow Coma Scale, provides a reliable assessment of CNS impairment and its progression over time.
The open label study enrolled 34 EHS patients between 18-45 years of age. The Company determined that this patient cohort was a sufficient number of subjects to enable assessment of a clinically meaningful treatment effect of RYANODEX in EHS.
Subjects were randomized 1:1 into two groups to receive either RYANODEX plus Standard of Care (“SOC”), which consists of body cooling by physical methods (e.g. cold water immersion, cold water mist, ice pack application) and supportive measures (Group A, n=17), or SOC alone (Group B, n=17).
Per study protocol, all subjects experienced exertional physical activity within the previous 24 hours, and demonstrated hallmark clinical features of EHS, including:
Presence of neurological impairment, evaluated using the Glasgow Coma Scale (“GCS”);
Baseline core body temperature of 104° F (40° C) or greater; and,
Tachycardia (at least 100 heart beats per minute)
Baseline disease characteristics were comparable between the two groups, including mean GCS score (Group A: 6.1 vs. Group B: 5.9) representing severe impairment, and mean core body temperature (Group A: 106.5° F (41.4° C) vs. Group B: 106.7° F (41.5° C).
Efficacy
Patients were evaluated at baseline and at regular time intervals post-randomization for changes in level of consciousness using GCS, core body temperature and renal, respiratory and cardiac functions. As illustrated by the table below, there was a greater proportion of patients at 90 minutes post-randomization in Group A as compared to Group B showing a GCS score ≥13, which indicates mild to no brain injury.
Cumulative Incidence of Glasgow Coma Scale (GCS) Score ≥13 at 90 Minutes Post-Randomization
Group A (RYANODEX + SOC)
(N=17)
Group B (SOC)
(N=17)
29.4% 11.8%
Furthermore, as shown in the table below, the proportion of patients achieving a GCS score ≥13 increased over time and was greater in Group A as compared to Group B, where the proportion of patients did not show further increase after 15 minutes post-randomization.
Cumulative Incidence of Glasgow Coma Scale (GCS) Score ≥13 Post-Randomization
Time post-randomization
Group A (RYANODEX + SOC)
(N=17)
Group B (SOC)
(N=17)
0-5 minutes 5.9% 5.9%
15 minutes 17.6% 11.8%
30 minutes 17.6% 11.8%
45 minutes 29.4% 11.8%
60 minutes 29.4% 11.8%
75 minutes 29.4% 11.8%
90 minutes 29.4% 11.8%
Safety
Overall safety findings were comparable between the two study groups, and there were no serious drug-related adverse events. Fewer patients experienced adverse events in Group A (58.8%), as compared to Group B (70.6%), and the overall incidence of serious adverse events (17.6%) in each of the two treatment arms was comparable. In summary, the safety results of the study are consistent with the known, and well characterized, safety profile of RYANODEX.
Next Steps
Eagle believes that these findings further support establishing the safety and efficacy of RYANODEX for the treatment of EHS, and support the expansion of the product’s label to include this indication. The Company continues to analyze the study data, and expects to discuss the full data and next steps with the FDA in the near future. Eagle will provide additional information in due course.
About the Glasgow Coma Scale
The Glasgow Coma Scale (“GCS”) is a validated tool that functions as a common scoring system among medical practitioners for measuring and describing the varying degrees of consciousness in a person following an acute brain injury.3
Widely accepted as reliable and objective, this scoring system is used by trained staff at the site of a potential brain injury, as well as in emergency departments and intensive care units. The GCS was selected for this study as an objective and accurate method to measure the state of mental impairment and the subsequent improvement of test subjects.
The GCS measures three key functions: Eye Opening, Motor Response and Verbal Response.
Eye Opening (E)
4 = spontaneous
3 = to voice
2 = to pain
1 = none
Motor Response (M)
6 = normal
5 = localized to pain
4 = withdraws to pain
3 = decorticate posture (an abnormal posture that can include rigidity, clenched fists, legs held straight out, and arms bent inward toward the body with the wrists and fingers bend and held on the chest)
2 = decerebrate (an abnormal posture that can include rigidity, arms and legs held straight out, toes pointed downward, head and neck arched backwards)
1 = none
Verbal Response (V)
5 = normal conversation
4 = disoriented conversation
3 = words, but not coherent
2 = no words, only sounds
1 = none
Clinicians use the GCS to assess the eye opening response, the verbal response, and the motor response in patients with an impaired level of consciousness. The total GCS score is the sum of the scores for each of these functions, classified as follows4:
Classification Total Glasgow Coma Scale Score
Severe
3 – 8
Moderate 9 – 12
Mild 13 – 15
About Exertional Heat Stroke
Exertional Heat Stroke (“EHS”) is a rare, sudden and unpredictable disorder that constitutes a medical emergency which may result in severe multi-organ dysfunction and death. EHS is more commonly seen in young people undergoing exertional physical activity in a hot weather environment, and is one of the leading causes of death in young athletes. EHS cases are also observed in construction workers, firefighters, military personnel, and farmers. There is no currently approved drug product for the treatment of EHS.
About Ryanodex
RYANODEX (dantrolene sodium) for injectable suspension is indicated for the treatment of malignant hyperthermia (“MH”) in conjunction with appropriate supportive measures, and for the prevention of malignant hyperthermia in patients at high risk.
Important Safety Information
RYANODEX is not a substitute for appropriate supportive measures in the treatment of malignant hyperthermia, including:
Discontinuing triggering anesthetic agents
Increasing oxygen
Managing the metabolic acidosis
Instituting cooling when necessary
Administering diuretics to prevent late kidney injury due to myoglobinuria (the amount of mannitol in RYANODEX is insufficient to maintain diuresis).
Precautions should be taken when administering RYANODEX preoperatively for the prevention of malignant hyperthermia, including monitoring vital signs, avoiding known triggering agents, and monitoring for early clinical and metabolic signs of malignant hyperthermia that may indicate additional treatment is needed.
The administration of dantrolene sodium is associated with loss of grip strength and weakness in the legs, as well as drowsiness, dizziness, dysphagia, dyspnea, and decreased inspiratory capacity. Patients should not be permitted to ambulate without assistance until they have normal strength and balance. Care must be taken to prevent extravasation of RYANODEX into the surrounding tissue due to the high pH of the reconstituted RYANODEX suspension and potential for tissue necrosis.
In February 2015, RYANODEX was granted seven years of U.S. market exclusivity for the treatment of MH by the U.S. Food and Drug Administration (“FDA”).
RYANODEX full Prescribing Information can be found at www.RYANODEX.com
About Eagle Pharmaceuticals, Inc.
Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle’s strategy is to utilize the FDA's 505(b)(2) regulatory pathway. Additional information is available on the company’s website at www.eagleus.com.
Forward-Looking Statements
This press release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995, as amended and other securities laws. Forward-looking statements are statements that are not historical facts. Words and phrases such as “will,” “may,” “intends,” “anticipate(s),” “plan,” “enables,” “potential,” “entitles,” “optimistic” “could” “look forward” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding future events including, but not limited to: the safety and efficacy of RYANODEX for the treatment of EHS; FDA approval of the use of RYANODEX for the treatment of EHS; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to manufacturing facilities, products and/or businesses; and other factors that are discussed in Eagle’s Annual Report on Form 10-K for the fiscal year ended September 30, 2014, and its other filings with the U.S. Securities and Exchange Commission. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond Eagle’s control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Such risks include, but are not limited to: whether the FDA will ultimately approve RYANODEX for the treatment of EHS; whether our studies will support the safety and efficacy of RYANODEX for the treatment of EHS; and other risks described in Eagle’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.
1 Szold et al. Gray–white matter discrimination—a possible marker for brain damage in heat stroke? European Journal of Radiology, Volume 43, Issue 1, July 2002 2 Sithinamsuwan et al. Exertional heatstroke: early recognition and outcome with aggressive combined cooling--a 12-year experience. Mil Med. 2009 May;174(5):496-502.
3 Teasdale G, Jennett B. (1974). "Assessment of coma and impaired consciousness. A practical scale." Lancet 13 (2): 81–4.
4 "What Is the Glasgow Coma Scale?" www.brainline.org, n.d. Web. <http://www.brainline.org/content/2010/10/what-is-the-glasgow-coma-scale.html>.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151217005649/en/
In-Site Communications, Inc.
Lisa M. Wilson, 212-452-2793
President
Oh Ralph...
$21's soon...
Looking great. SAVE for president 2016.
Virgin America Inc. (Nasdaq:VA) to Ring The Nasdaq Stock Market Closing Bell
Source: GlobeNewswire Inc.
What:
Virgin America (Nasdaq:VA), the California-based airline known for reinventing flying, will visit the Nasdaq MarketSite in Times Square in celebration of its new Airbus A321neo order.
The airline has announced it has agreed to acquire 10 new state-of-the-art Airbus A321neo aircraft, which are up to 20 percent more fuel and carbon efficient than the airline’s current fleet and which will help further reduce operating unit costs and increase revenue opportunities. The 10 new A321neos (short for New Engine Option), which provide the best seat-mile costs of any single-aisle aircraft on the market, are slated for delivery beginning in the first quarter of 2017 continuing through the third quarter of 2018.
In honor of the occasion, Virgin America President and Chief Executive Officer, David Cush and Chief Financial Officer, Peter Hunt, will ring the Closing Bell.
Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
When:
Wednesday, December 16th, 2015 – 3:45 p.m. to 4:00 p.m. ET
Virgin America Media Contact:
Dave Arnold
(917) 968-3622
dave.arnold@virginamerica.com
Nasdaq MarketSite:
Emily Pan
(646) 441-5120
emily.pan@nasdaq.com
Feed Information:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK
Nasdaq Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.
For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq
For news tweets, please visit our Twitter page at: http://twitter.com/nasdaq
For exciting viral content and ceremony photos visit Tumblr Page: http://nasdaq.tumblr.com/
Virgin America Social Media:
For photos from the ceremony and other events visit our Instagram Page: http://instagram.com/virginamerica
For news tweets, please visit our Twitter page at: http://twitter.com/virginamerica
Webcast:
A webcast of the Nasdaq Closing Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos:
To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.
About Virgin America:
Known for its mood-lit cabins, three beautifully designed classes of service and innovative fleetwide amenities — like touch-screen personal entertainment, WiFi and power outlets at every seat, Virgin America has built a loyal following of flyers and earned a host of awards since launching in 2007 — including being named the "Best U.S. Airline" in Condé Nast Traveler's Readers' Choice Awards years and "Best Domestic Airline" in Travel + Leisure's World's Best Awards for the past eight consecutive years. For more: www.virginamerica.com
About Nasdaq:
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,600 listed companies with a market value of approximately $8.8 trillion and more than 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.
-NDAQA-
Primary Logo
Yeah but JBLU and LUV just guided down Q4 numbers so I understand that beat down. But AAL...no dice.
True, true, true, and true I must say.
Yeah Ralph I don't get why it's stuck in the range $38-$47. Ever since 2014. Both good and bad catalysts have the same effect. It's pretty sad actually. Only so long oil can stay this low.
Only so long they can make these profits. Wall Street just really hates this company. I think they really just hate Doug to be honesty. That's the ONLY variable that hasn't changed.."Doug".
Good time for profit taking in the market. All stocks getting raped. Many exiting and tax selling. I'll be buying some carriers for the cheap soon.
I'd be buying here on down to sub $40, maybe even $38 for a strong sell at $44-$47.
Same thing they said end of 2014, yet here we are 6.5% lower than where we ended that year.
I've said repeatedly til I was blue in the face, they'll make $44-$47 the 1 year target according to those analyst targets several months back. Just can't shake this $38-$47 range. We are the only ones who see this as a $60 stock.
Pretty strong traffic actually. PRASM not so much.
Just bought partial fluff back at $23.70 a little bit ago. Called it on StockTwits. Got another bid below. I'll sell anything over $25.
Hence I like SAVE, VA, HA 2016.
They'll find a way to spin this oil falling (capacity, price war).
Like clock work
Better chance of getting love if oil was $75
Yeah 2036 is my call!
"Capacity concerns" "price wars". Predictable cycle. By sub $40 here and sell anything over $44-$47. I'm going shopping and flipping ahead of earnings on select carriers.